yahoo.comSep 1$ELMD

Electromed (ELMD) Q4 2026 Earnings Call Transcript

Electromed (ELMD) reported Q4 2026 revenue growth of 11.6% to $19.4M, with full-year revenue up 15.3% to $73.8M. Growth was driven by home care and distributor channels, while hospital revenue declined 29%. The company expanded its sales force and highlighted its SmartVest product's market potential. CEO Jim Armstrong announced his planned retirement in April 2027.

Original reporting

yahoo.com

Published Sep 1, 2026, 11:00 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 1, 2026, 11:33 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Electromed (ELMD) Q4 2026 Earnings Call Transcript — source image — Source · yahoo.com

Decision brief

The 30-second read

$ELMDNeutralMed

Why it matters

Earnings beat and strategic initiatives may support price appreciation, while CEO succession adds execution risk.

Market read

First disclosure of FY 2026 financials and leadership change for a micro‑cap med‑tech firm.

What to watch

Pending CMS rule change in 2028 could boost demand for electronic order solutions.

Relevance 6/10Novelty 7/10Timing: post‑earnings Q4 2026 release

Background

Electromed (ELMD) reported Q4 2026 results, detailing revenue growth, channel performance, payer contracts, and CEO retirement.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ELMDNeutralMedium confidence

Context

Q4 2026 earnings call disclosed net revenue of $19.4M and FY 2026 revenue of $73.8M, plus CEO retirement announcement.

Expected impact

Potential modest upside if market rewards growth and smooth succession; downside risk if transition concerns dominate.

Evidence & confidence

Growth rates are solid for a micro‑cap, but absolute dollar size is small and leadership change adds uncertainty.

Market effects

Sector

Highlights growth potential in home‑care medical devices and bronchiectasis treatment market.

Regional

U.S. focused; may influence other small‑cap med‑tech stocks.

Global

Limited to niche medical device sector.

Counterpoint

What could challenge this read

Leadership turnover could signal deeper operational issues, warranting a short stance.

Key entities

Company
Electromed
Medical device maker focused on SmartVest therapy.
Executive
Jim (CEO)
Announced retirement effective April 2027.

Read at source ← All news

$ELMDHigh

Electromed, Inc. Delivers Continued Growth in Fiscal 2027 First Quarter

Electromed, Inc. (ELMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Electromed, Inc. Delivers Continued Growth in Fiscal 2027 First Quarter 16th consecutive quarter of year-over-year revenue and operating income growth NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. (“Electromed”) (NYSE American: ELMD), a leader in innovative a

SEC EDGAR 8-KNov 10

Med

Electromed, Inc. Q4 2026 Earnings Call Summary

Electromed, Inc. reported 15% Q4 home care revenue growth and 29% hospital revenue decline, driven by sales and longer sales cycles. The company expects double-digit growth in 2027, with strategic investments in digital solutions and sales force expansion. CEO James Cunniff will retire in April 2027. The company aims to expand payer coverage and product lines.

yahoo.comAug 27

$ELMDMed

Electromed, Inc. Announces Record Fiscal 2026 Fourth Quarter and Full Year Financial Results

Electromed, Inc. (ELMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Electromed, Inc. Announces Record Fiscal 2026 Fourth Quarter and Full Year Financial Results Strong homecare revenue growth and expanded operating leverage drive record operating income in Fiscal 2026 NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. (“Electromed

SEC EDGAR 8-KAug 25

$RTXMed

RTX sees margin expansion, cash flow growth in 2027 (RTX:NYSE)

RTX anticipates a $500 million cash flow boost from reduced powdered-metal payments in 2027, partially offset by other factors. The company plans to focus on investments, dividends, debt reduction, and acquisitions.

seekingalpha.comNov 10

$INOHighAI 8/10

Inovio Q3 2026 slides: VOCERYQ approval amid wider loss

Inovio Pharmaceuticals reported a Q3 2026 net loss of $49.2M, wider than expected, despite FDA approval of VOCERYQ. Shares fell 3.97% to $1.45, then another 10.34% after hours. Operating expenses declined 7% YoY, but non-cash losses increased. Cash reserves total $48.4M, with a runway into late 2027. VOCERYQ targets recurrent respiratory papillomatosis, showing 50-100% surgery reduction in trials. The company plans a Q1 2027 launch and European filings by year-end.

investing.comNov 10

$ASTSMed

AST SpaceMobile (ASTS) Stock Price Faces Q3 Results And Cash Burn

AST SpaceMobile (ASTS) reported a Q3 loss of $132.4M and a 12-month loss of $628.3M, with adjusted operating expenses rising and capex guidance for Q4 at $400M-$500M. Bearish analysts warn of heavy cash burn before wholesale revenues scale, with satellite deployments delayed until 2027.

finance.yahoo.comNov 10